TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Freezing index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean incontinence score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fungal colonisation index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Positive tracheal cultures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Increased colony counts or new organisms in tracheal aspirates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: clinically significant reduction of cerebral saturation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Ultrafiltration decline during standardized PET
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peritonitis rate
Endpoint domain: Adverse events/effects
Primary endpoint: 10-metre walk test duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: time of recovery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: time of hospitalization
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Reduction of lower limb edema
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in left ventricular end-systolic volume (ESVi)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Reduction in left ventricular end-diastolic volume (EDVi)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in left ventricular ejection fraction (EF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: AUC(tau,ss) of tolterodine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: C(max,ss) of tolterodine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: t(1/2) of tolterodine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: decision authority
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Taste acuity recovery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median time to sustained cessation of infectious virus detection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median time to alleviation of symptoms
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Rate of HF hospitalization
Endpoint domain: Mortality/survival
Primary endpoint: Percentage of days lost to HF hospitalizations or death
Endpoint domain: Mortality/survival
Primary endpoint: Percentage of days lost owing to all-cause hospitalization or death
Endpoint domain: Mortality/survival
Primary endpoint: prevalence of binge drinking
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: TDI score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: rescue albuterol use
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: hyperemic peak flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: flux recovery time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: hyperemic curve area after ischemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tensile bond strength values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ischemic stroke occurrences
Endpoint domain: Adverse events/effects
Primary endpoint: treatment failure (HIV-1 RNA >50 copies/ml)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Geometric mean antibody titers (GMTs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: subjective prognosis of future employment
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: global satisfaction score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: mental component summary of the SF-36v2
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: competitive employment
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: work hours
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: work weeks
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Maximum endurance time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinically important gastrointestinal bleeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Auxiliary treatment rate
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Renal SFR
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in total OABSS from baseline to 12 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of life improvement in BPH patients with OAB
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: mean decentration of IOLs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean tilt of IOLs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients with pVL <50 copies/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Time to pVL <50 copies/mL for the first time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ability to correctly determine glycemic risk
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Confidence in determining glycemic risk
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Intrarater agreement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Interrater agreement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Near visual acuities
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fluorescein angiographic findings
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Operative and hospitalization times
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Short-term recurrence rate
Endpoint domain: Adverse events/effects
Primary endpoint: SF-36 functioning score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Short Musculoskeletal Functional Assessment musculoskeletal functioning
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Incident prediabetes
Endpoint domain: Mortality/survival
Primary endpoint: Incident type 2 diabetes mellitus
Endpoint domain: Mortality/survival
Primary endpoint: major vascular complications
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: sensitivity for pulmonary nodule detection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Primary efficacy endpoint
Endpoint domain: Adverse events/effects
Primary endpoint: Corneal swelling percentage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Geometric mean titers of antibody to varicella
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: half-life values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: any colorectal neoplasia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: risk of SSA/P
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Parents-child separation assessment
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: insulin resistance (HOMA-IR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: LDF value for bone vascularity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cardiovascular death or non-fatal myocardial infarction
Endpoint domain: Mortality/survival
Primary endpoint: Revascularization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Duration of motor and EEG seizures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall quality of life index
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Survival rates after operation
Endpoint domain: Mortality/survival
Primary endpoint: long-term efficacy of beta-blocker therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improved treatment outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Consultation rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean maximal plasma amitriptyline concentration (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean time to maximum concentration (tmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: bioavailability of amitriptyline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: GR and rCAL gain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: developmental outcome at age two years
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Need for intravenous morphine postoperatively
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Rate of hypoglycemia episodes
Endpoint domain: Adverse events/effects
Primary endpoint: Seroconversion for Gardasil
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Noninferiority of immune responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: percent reduction in the number of inflammatory and noninflammatory lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: clinician's global assessment improvement
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Regression of NVD to less than or equal to one-third disc area
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mortality rate at 30-day follow-up
Endpoint domain: Mortality/survival
Primary endpoint: Improvement in primary care management
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Need for rescue antiemetic to treat PONV
Endpoint domain: Adverse events/effects
Primary endpoint: Improvements in 3MSCT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvements in 6MWT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in total Equivalence Age
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: volume of secretions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Withdrawal rates
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Conicity Index (CI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: 1-hour morning postdose FEV1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: rate of moderate/severe exacerbations
Endpoint domain: Adverse events/effects
Primary endpoint: pupae per person index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: house index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: container index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in HbA1c from baseline to endpoint
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage of patients achieving HbA1c ≤ 6.5%
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Serum cholesterol improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: 12-month primary patency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: 12-month secondary patency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: unassisted use for hemodialysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: incidence of cerebral hemorrhage transformation
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of subjects with AMS (LLS>3)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum iron concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Transferrin saturation rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Cardiovascular mortality ratio
Endpoint domain: Mortality/survival
Primary endpoint: Serum Golimumab Concentrations (SGCs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in peak plantar flexion moment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: PTSD symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: scar contour
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Psychosis/mania adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of neuropathic pain (NP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Moderate/intense pain (visual analog scale, ≥4.0)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Apparent volume of lung tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Tumor distinguishability from surroundings
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: reported sexual aggression likelihood
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: recurring episode of NAEB
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of procedural major adverse cardiovascular events
Endpoint domain: Adverse events/effects
Primary endpoint: Osteotomy compression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Stability of CLO graft
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Instrumental Activities of Daily Living
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Physical Activity Scale of the Elderly
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Proportion of participants increasing activity above 120 minutes of moderate intensity activity per week
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain scores 6 hours after surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increases in primary care visits
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Increases in self-help visits
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Increases in appropriate treatment for community clients
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Gain of clinical attachment (CAL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pocket probing depth
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Alpha‐2‐macroglobulin levels in GCF
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage change from baseline in total hip BMD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage change from baseline in femoral neck BMD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: improvement in motor performance of the affected hand
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Effectiveness of MAOI and SSRI in treating SP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maintenance of response with continued treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of relapse after early termination of treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total Lung Capacity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Nocturnal confirmed hypoglycaemic episodes
Endpoint domain: Adverse events/effects
Primary endpoint: Total confirmed hypoglycaemic episodes
Endpoint domain: Adverse events/effects
Primary endpoint: Number of patients discharged within 2 hours
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Mean ovarian volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Major adverse cardiac or cerebrovascular events
Endpoint domain: Mortality/survival
Primary endpoint: LPSS values in RV and LV
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Average number of goblet cells per high-power field
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: serum triglycerides reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Total effective rate of anti-spasticity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mortality to 28 days after treatment
Endpoint domain: Mortality/survival
Primary endpoint: Number of nonpulmonary organ failure‐free days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: hypercapnic ventilatory response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: hypercapnic respiratory-drive response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: ratio of hypercapnia-test P(0.1) to baseline P(0.1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Trait anxiety
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Response rate for physicians
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Risk of thrombosis perception
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Postoperative narcotic and acetaminophen requirements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: level of vascularization in the osteoligamentous interface
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Basal volumes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Effectiveness of Alefacept in psoriasis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Activated clotting time (ACT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in periodontal condition
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: living situation
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: interfacial strength between resin composite and root canal walls
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time without symptoms, treatment, and treatment toxicity (TwiSTT)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Detection rate of sentinel nodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Lymphatic system outcomes
Primary endpoint: Visualization rate of sentinel nodes by lymphoscintigraphy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Lymphatic system outcomes
Primary endpoint: Improvement in knowledge questions answered correctly
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Planned PSA test uptake
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Distant Progression-Free Survival (DPFS)
Endpoint domain: Mortality/survival
Primary endpoint: students' satisfaction/engagement
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: recall
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Reduction in total tic score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Symptom and physical signs score of low back pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Score of cold-damp syndrome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: weekly urinary incontinence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: axillary pathological complete remission (pCR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Detection of endometrial abnormality
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Response rate (≥ 50% reduction of MADRS total score)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Remission rate (MADRS total score of ≤8 at endpoint)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: tumor growth rate constants
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: RDQ mean value change
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning